Business UpdateMay 15, 2026, 11:02 AM
Myriad Genetics Partners Jackie Tohn for Cancer Testing Awareness
AI Summary
Myriad Genetics, Inc. announced a partnership with actress Jackie Tohn to raise awareness about the importance of hereditary cancer testing using its MyRisk ® Hereditary Cancer Test. Tohn shared her personal story of discovering a BRCA1 gene variant through testing, which led her to undergo prophylactic surgery. The campaign emphasizes early detection and personalized risk management for 11 cancer types, highlighting risk factors and the test's comprehensive assessment, particularly for individuals with family history or Ashkenazi Jewish ancestry.
Key Highlights
- Myriad Genetics partnered with actress Jackie Tohn to raise awareness for hereditary cancer testing.
- Jackie Tohn discovered a BRCA1 gene variant using the MyRisk ® Hereditary Cancer Test.
- Tohn learned she had an 85% chance of breast cancer and 65% chance of ovarian cancer.
- The MyRisk ® test evaluates 63 genes to assess hereditary risk across 11 cancer types.
- RiskScore ® combines history and ~150 genetic markers for breast cancer risk assessment.
- More than one in four women in an OB-GYN setting meet criteria for hereditary cancer testing.
- 1 in 40 Ashkenazi Jewish individuals carry a BRCA1/2 gene mutation.
- Myriad Genetics has tested over 3 million patients in hereditary cancer testing over 30 years.
Price Impact
More from MYGN